Recently, Bosheng Jianko, a shareholding company of Anke Biotech, announced that it has completed the first patient administration of its self-developed vivo cell therapy product LV009 injection, marking that Bosengji's CAR-T/NK technology has officially moved from “in vitro customization” to a new era of “in vivo generation.” LV009 has achieved efficient transfection of resting T cells and NK cells through breakthrough lentivirus vector technology. It can simultaneously generate CAR-T and CAR-NK cells targeting CD19, which is expected to bring disruptive breakthroughs in B-cell malignant tumor treatment.

Recently, Bosheng Jianko, a shareholding company of Anke Biotech, announced that it has completed the first patient administration of its self-developed vivo cell therapy product LV009 injection, marking that Bosengji's CAR-T/NK technology has officially moved from “in vitro customization” to a new era of “in vivo generation.” LV009 has achieved efficient transfection of resting T cells and NK cells through breakthrough lentivirus vector technology. It can simultaneously generate CAR-T and CAR-NK cells targeting CD19, which is expected to bring disruptive breakthroughs in B-cell malignant tumor treatment.